InsiderTrades

Form 4 for BSX Boston Scientific

Accepted 2025-06-04 00:00:00 ET · period of report 2025-06-04 · accession 0001225208-25-005721 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-06-04 2025-06-04 BSX Fitzgerald Joseph Michael EVP, Group Pres, Cardiology M - OptEx $26.15 +56.4K 234.7K +32% +$1.47M
D 2025-06-04 2025-06-04 BSX Fitzgerald Joseph Michael EVP, Group Pres, Cardiology S - Sale+OE $102.88 -56.4K 178.3K -24% -$5.80M
D 2025-06-04 2025-06-04 BSX Fitzgerald Joseph Michael EVP, Group Pres, Cardiology M - OptEx $0.00 -56.4K 250.0K -18% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-06-04 M A 56,372 $26.15 234,714 D — —
2 Common Common Stock 2025-06-04 S D 56,372 $102.88 178,342 D — — (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.46 to $103.42, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3 Derivative Stock Option (Right to Buy) 2025-06-04 M D 56,372 $0.00 250,000 D $26.15 · — to 2027-12-01 56,372 Common Stock (F4) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.